Health
Orally administered experimental drug halts SARS-CoV-2 replication, prevents infection – News-Medical.Net
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental…
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate phase 2 and 3 clinical trials are ongoing to evaluate EIDD-2801 safety in humans and its effect on viral shedding in COVID-19 patients.
The number of new COVID-19 cases continues to…
-
Noosa News21 hours agoTrucking company penalised for refusing to pay unfairly sacked worker
-
Noosa News16 hours agoTallest tower outside CBD approved for construction at 205 metres
-
Noosa News17 hours agoFarmgate Backpackers leads with integrity amid industry challenges
-
General23 hours agoVacherot becomes lowest-ranked ATP Masters winner after defeating his cousin Rinderknech in Shanghai